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1. Introduction
The establishment of pluripotent mouse embryonic stem cells (ESCs), which have the capacity
to differentiate into all cell types in the mammalian body, was first described by Evans and
Kaufman in 1981. Seventeen years later, in 1998, the first report of human ESCs, with similar
differentiation characteristics was published by James Thompson. In 2006, Takahashi and
Yamanaka discovered that the genome of a differentiated somatic cell could be epigenetically
reprogrammed to pluripotency by inducing the expression of pluripotency transcription
factors, resulting in the production of pluripotent stem cells (iPSCs). This research has
accelerated the study of regenerative medicine.
In 2009, the US Food and Drug Administration approved the first Phase I clinical trials of
human ESC-derived cells for the treatment of spinal cord injuries. However, previous reports
had revealed that stem cell-based therapies increase the risk of tumor development. Therefore,
further basic research is needed before stem cell-based therapies can be applied in the clinic.
The development of stem cell tools can be critically evaluated using animal models that express
human disease genes.
Research on the stem cell biology of the minipig is developing rapidly. Although research on
mouse and human stem cells currently predominates over that in other species, data from these
well-studied species have provided a good foundation for current and future porcine stem cell
research. In addition, the increasing popularity of alternative-species models for the study of
human diseases and disease mechanisms has further spurred porcine stem cell research. As a
model system for pluripotent embryonic stem cell research, however, the pig presents several
challenges as compared with mice and humans. Nonetheless, porcine minipig embryonic germ
cells have recently been produced, and may prove particularly useful for in vitro and in vivo
differentiation studies, gene targeting, and the creation of transgenic animals. In addition,
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studies involving the transplantation of somatic mesenchymal stem cells into porcine heart,
cartilage, and bone have yielded very promising results. Lastly, minipig induced pluripotent
stem cells have been established by using Sendai viruses to introduce pluripotency transcrip‐
tion factors into the cells.
Thus, despite the challenges of developing porcine pluripotent stem cells, recent successes in
the fields of both induced pluripotent stem cells and somatic stem cells suggest that the future
of research using minipig stem cells is quite promising.
2. Embryonic stem cells
Most porcine embryonic stem cell research has been performed in large domestic pig breeds
rather than minipigs. Therefore, this discussion will focus on studies performed on the large
domestic breeds, yet with attention paid to outcomes observed in the minipig. Research in the
domestic species is highly transferrable to the minipig.
Although researchers have sought to establish ESCs in the pig, the characterization of ESCs in
this animal falls short, due to a lack of both in vivo and long-term culture studies as compared
to ESCs of mouse or human origin. The first reports on ESC production in the pig were in 1990
[1] [2] [3] [4]. However, those attempts produced only putative ESCs or embryonic stem-like
cells.
A number of standard techniques are typically employed to verify the identity of true ESCs.
Several in vitro techniques are generally performed to determine the expression profile of the
ESCs, including gene-expression and protein analyses. The transcription factors expressed in
both mouse and human ESCs include OCT4, NANOG, and SOX2. In addition, stage-specific
embryonic antigen 1 (SSEA1) is expressed in mouse but not human ESCs, and SSEA3 and
SSEA4 are detected in human but not mouse ESCs [5].
While the efforts to establish porcine ESCs have been well reviewed in the scientific literature
[6] [7], a general overview of the research suggests that true porcine ESCs have not yet been
produced. The production of porcine epiblast stem cells (EpiSCs) was recently reported [8].
These cells are thought to be derived from the epiblast, rather than the inner cell mass, of the
developing embryo. Evidence suggests that mouse ESCs are of inner cell mass origin, while
human ESCs originate from epiblasts [9]. The porcine epiblast stem cells could be cultured for
22 passages, and could differentiate in vitro into cell types representative of the three embryonic
germ lineages as well as germ precursor cells and trophectoderm. However, it is not known
whether these cells also demonstrate pluripotency.
To date, two research groups have attempted to produce porcine ESCs from the minipig [10,
11]. Li and colleagues reported that outgrowth cultures could be obtained after isolating the
inner cell mass from Chinese minipig blastocysts, although sustained culture was difficult to
achieve, and only a preliminary characterization of these cells was performed [10]. Long-term
cultures of porcine ESC-like cells were reported by Kim and colleagues [11]. In this study,
porcine ESC-like cells were derived from cloned blastocysts. These embryos were produced
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by somatic cell nuclear transfer, using minipig fetal or neonatal fibroblasts as the donor and
prepubertal gilt oocytes, followed by culture in vitro to the blastocyst stage of development.
Two cells lines could be cultured for more than 48 passages, and expressed alkaline phospha‐
tase (AP), SSEA1 and SSEA3, OCT4, TRA-1-60, and TRA-1-81. The only method used to
characterize their differentiation ability was the observation of spontaneous differentiation
into embryoid bodies (EBs), which are spheres of cells that contain cell types of all three germ
layers. These EBs were assessed solely by gene analysis, thus further characterization would
be necessary before they could be verified as true ESCs.
Only two reports to date describe the production of chimeras from porcine ESC-like cells: one
in 1999, from Chen and colleagues [12], and a more recent publication in 2010 [13]. The first
report claimed that somatic chimeric piglets could be produced, although clear analyses of
these chimeric animals was lacking. The second report indicated that porcine ESC-like cells
from an early passage could form chimeric piglets. The chimeric contribution was low,
however; only 4 chimeric piglets were born after the transfer of hundreds of embryos. Only 2
of the 4 chimeric piglets showed coat chimerism, and this contribution was low and restricted
to a single spot near the tail. Such a chimeric contribution is much lower than what would be
expected from mouse ESCs, indicating that improvements to the cell culture conditions may
be required to improve the plasticity of these cells.
There are several possible reasons for the difficulty in producing porcine ESCs. The lack of
defined culture conditions may be one reason. Pluripotency appears to be controlled by more
than one cell-signaling pathway, and these pathways are different in mouse and human ESC
lines. The origin of the cells, that is, the inner cell mass (mouse) versus the epiblasts (human)
may contribute to this diversity of regulatory pathways. This idea is supported by a recent
publication showing that even mouse EpiSCs regulate pluripotency slightly differently from
human ESCs [14]. The cell signaling that governs pluripotency in the pig remains largely
unknown, although the details are beginning to be investigated [15]. For example, it was
reported that fibroblast growth factor (FGF) signaling may be active in porcine epiblasts, and
that the JAK/STAT pathway is inactive. The Activin/Nodal pathway also appears to be active
in porcine epiblasts [8]. Culturing porcine epiblasts in medium containing basic FGF (bFGF)
cannot prevent their differentiation, indicating that other factors are apparently necessary to
help maintain cellular pluripotency.
Differences occurring during early embryonic development in the domestic pig, as compared
with mouse and human, could also account for the observed difficulties in producing porcine
ESCs. The early development of the porcine embryo prior to implantation takes longer and is
less advanced than in the other species. The inner cell mass differentiates into the hypoblast
and epiblast at a later time point than in the mouse and human, and the porcine epiblast
expands and develops over a period of several days. The cell signaling controlling this
development in the pig could differ markedly from that in the mouse or human, and should
be investigated to ascertain which stage of development is optional for isolating the pluripotent
cells. It is possible that the later epiblast is already predetermined at the cell-signaling level to
undergo gastrulation, or that the inner cell mass cells have not yet acquired the necessary cell
signaling machinery to support proliferation.
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We have yet to observe bona fide ESCs produced from the pig. Nevertheless, continued research
toward this goal is important, as the pig is a particularly useful biomedical model for studying
human disease, and ESCs are a unique cell type that is especially useful for studying human
disease.
3. Embryonic germ cells
Embryonic germ cells (EGCs) are pluripotent cells derived in vitro from primordial germ cells
(PGCs). They were first derived in the mouse by Matsui et al. [16] and Resnick et al. [17]. Mouse
EGCs are morphologically similar to mouse ESCs, and express similar pluripotency markers
such as AP, SSEA1, Oct4, Sox2, and Nanog. The differentiation potential of these cells is also
similar to that of mouse ESCs, as evidenced by their ability to differentiate in vitro into different
tissues from the three primary germ layers [18], as well as to re-enter the germline when
injected into blastocyst embryos [19]. Mouse EGCs may thus be considered equivalent to ESCs.
Similar to the conditions required to derive mouse ESCs, mouse EGCs need two important
growth factors in addition to leukemia inhibitory factor (LIF) for their successful derivation
from PGCs. The first is stem cell factor (SCF), a ligand for c-Kit, which supports PGC survival
in vivo and in vitro by suppressing apoptosis [20]. The second is bFGF, which plays a major
role in the reprogramming of mouse PGCs into pluripotent cells in vitro [21]. Although the
mechanism of this reprogramming is still poorly understood, bFGF is known to downregulate
the expression of basic lymphocyte maturation protein 1 (Blimp1) in vitro, which in turn causes
the upregulation of c-Myc and Klf4 [21]. Because mouse PGCs also express Oct4 and Sox2, a
similar mechanism may be involved in their reprogramming to ESCs.
Porcine EGCs were first derived by Shim et al. [22], who used embryos from domestic breeds
on day 25 of gestation under conditions similar to those used to culture mouse EGCs. The
established cell lines had an ESC-like morphology, expressed AP, and were able to differentiate
into different cell types in vitro and in vivo. Other groups have derived porcine EGC lines using
day 25-28 embryos from domestic breeds [23] [24] [25] [26] [27], and from the Chinese minipig
[28]. Recently, putative porcine EGC lines derived from the PGCs of day 20-24 embryos from
Danish Landrace crosses and Yucatan minipigs were reported [29]. Notably, these findings
suggest that EGC lines can be established from any porcine breed, unlike mouse ESCs, which
are restricted to certain strains.
Immunocytochemical analysis of pluripotency marker expression showed that, in addition to
AP activity, EGCs express Oct4, SSEA1, SSEA3, and SSEA4 at variable levels. Analysis of the
porcine EGC gene expression suggested that they are similar to human EGCs in expressing
AP, Oct4, SSEA1, and SSEA4 [30]. The pig EGCs typically have long cell cycles, and proliferate
slowly over many passages.
The tissue culture conditions used by all groups for the derivation and propagation of porcine
EGCs are similar to those used for human and mouse ESCs. The cells are grown on feeder
layers of mitotically inactivated embryonic mouse fibroblasts, most often on immortalized
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mouse fibroblast cells from a cell line known as STO. The initial establishment of cell lines is
hampered by the fact that large numbers of porcine PGCs undergo apoptosis and die in culture
within 6 hours of their incubation [25]. However, by using protease inhibitors and antioxidants
to reduce the level of PGC apoptosis in vitro, Lee et al. were able to increase the number of EGC
colonies in the primary culture. In addition, alpha 2-macroglobulin together with N-acetyl‐
cystein and butylated hydroxyanisole (both antioxidants) increased the number of AP-positive
colonies in primary cultures at least twofold. Another approach is to use growth factors and
various feeder cells to increase the survival and prevent the differentiation of PGCs in long-
term culture. Lee et al. [26] showed that supplementing the culture medium with three growth
factors (LIF, SCF, and bFGF) increased the number of colonies obtained in primary culture,
and improved the quality of the colonies in subsequent passages compared to cells treated
with only two of these growth factors. The use of feeder layers other than STO cells did not
have a significant effect on PGC survival or on the quality of the derived EGCs. In another
study, membrane-bound SCF and soluble LIF were sufficient to increase the number of
surviving PGCs on days 3 and 5 of primary culture, while adding bFGF did not affect the
results significantly [23]. It is possible that the membrane-bound form of SCF is more potent
than the soluble form, which could explain these differing results. However, it has also been
reported that established PGCs are capable of generating chimeras without added growth
factors, while adding LIF to the culture does not improve the efficiency of establishing EGC
lines [22]. Thus, further study is needed to elucidate the effects of these supplements in culture.
Pluripotent stem cells are able to form EBs, spherical aggregates containing differentiated
cells, when cultured in suspension. Porcine EGCs cultured in “hanging drops” can also form
simple EBs, consisting of large epithelial-like cells on the periphery surrounding mesenchy‐
mal-like cells in the center. When allowed to attach to gelatin-treated plastic dishes, the EB
cells proliferate and spread on the surface of the dish, giving rise to several different types
of cells [27].
Pluripotent cells can proliferate and differentiate in vivo, forming tumors containing differen‐
tiated tissues called teratomas, when injected into immunodeficient mice. To date, only one
group has reported teratoma testing for porcine EGCs, using cell lines derived from the
Chinese minipig [28]. The authors reported that the teratomas contained cells from the three
primary germ layers: epithelial, neuroepithelial, and adipose tissue. In contrast to these results,
two studies showed that the injection of human EGCs into immunodeficient mice failed to
generate teratomas. [31] [32]. However, more recently, the formation of teratomas from human
EGCs cultured under serum-free conditions was reported [33].
Another way of testing the differentiation potential of pluripotent cells in vivo is by chimera
formation, in which the cells injected into early embryos contribute to the three germ layers
and potentially to the germline. Unlike mouse ESCs and EGCs, which have been shown to re-
enter the germline of chimeras, pig EGC chimeras have not displayed a proven germline
contribution; furthermore, the somatic tissues of these porcine chimeras contained only a low
percentage of donor-derived cells [22] [34] [24]. Other researchers demonstrated a similarly
low chimeric contribution after the injection of somatic cells into sheep blastocysts and 8-cell
mouse embryos [35, 36]. This is troubling because germline contribution is considered to be
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the ultimate proof of pluripotency, and has been demonstrated only in the mouse and chicken
to date. Human ESCs are presumed to be true stem cells as well, even though their germline
potential has not been tested for ethical reasons. Caution is needed when interpreting chimera
experimental results. Proper controls are necessary to distinguish the “true” stem cells from
somatic cells that can be integrated into the embryos after partial reprogramming by the
surrounding embryonic cells.
The reasons for the limited pluripotency of the porcine EGCs are currently unclear. It is possible
that the tissue culture conditions are not sufficient for maintaining the pluripotency of the
PGCs in vitro, similar to the problems that exist in the cultures of inner cell mass and epiblast
cells. Another possibility is that the pig PGCs do not undergo full epigenetic reprogramming
into pluripotency like the mouse PGCs do. One indication that there might be differences in
the biology of PGCs between the pig and mouse is that porcine PGCs survive and proliferate
in vitro in the absence of externally added growth factors, regardless of whether they are
cultured in serum-supplemented or serum-free conditions, while mouse PGCs fail to survive
in the absence of any of the three growth factors LIF, SCF, or bFGF. In addition, mouse PGCs
have not been shown to form chimeras, whereas porcine PGCs can contribute to somatic tissues
after their injection into early blastocysts [24]. Thus, some of the molecular mechanisms that
are important for reprogramming mouse PGCs to pluripotent EGCs in culture may be different
in the pig.
4. Induced pluripotent stem cells
Takahashi and Yamanaka [37] discovered that the genome of a differentiated somatic cell can
be epigenetically reprogrammed to pluripotency by the induced expression of pluripotency
transcription factors, resulting in the generation of pluripotent stem cells [induced Pluripotent
Stem Cells (iPSCs)]. These authors initially expressed 24 pluripotency genes in fetal fibroblasts
to reprogram them into pluripotent cells, and subsequently found that the expression of only
4 of these genes, namely Oct4, Sox2, c-myc, and Klf4, was sufficient to achieve the same results.
Nanog was dispensable for the cellular reprogramming. In addition, a year later, Okita et al.
[38] produced germline-competent mouse iPSCs using the same growth factors, but by
selecting the reprogrammed cells by Nanog expression.
The production of human iPSCs started shortly after the publication of the first report of mouse
iPSC derivation. Thus, it was not surprising that the establishment of the first human iPSCs
was reported by two groups simultaneously. The laboratory that produced the first mouse
iPSCs successfully generated iPSCs from adult human fibroblasts by using the same 4
transcription factors employed in the initial experiment [39]. The other group, from the
laboratory of human ESC pioneer James Thompson, was able to reprogram human fibroblasts
by expressing OCT4, SOX2, NANOG, and LIN28 [40].
Predictably, these studies sparked significant interest among researchers working in the area
of porcine pluripotent cells. Within two years after the publication of the first papers describing
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human and mouse iPSCs, three different groups reported the establishment of iPSCs in the
pig. One of these groups generated porcine iPSCs using fetal fibroblasts from Danish Landrace
pigs, by the lentiviral transduction of six human transcription factors (OCT4, SOX2, c-Myc,
KLF4, LIN28, and NANOG) under the control of a doxycycline-inducible promoter [41].
Simultaneously, another Chinese group reported the derivation of iPSCs from fibroblasts from
the Tibetan minipig, using constitutively expressed lentiviral vectors carrying the mouse
cDNA sequences of Oct4, Sox2, c-myc, and Klf4 [42]. The third report published shortly
thereafter by Ezashi et al. [43] also described the production of porcine iPSCs through the use
of 4 human transcription factors (OCT4, SOX2, c-Myc, and KLF4). In addition, these researchers
claimed that the porcine iPSCs were positive for SSEA-1 but negative for SSEA3 and SSEA-4,
indicating that they were more similar to mouse than human iPSCs.
Transcriptional profiling of the cell line by Affymetrix microarray confirmed that the cells were
indeed reprogrammed, and expressed a variety of ESC markers endogenously. However, the
continued expression of the exogenous transcription factors was detected in the iPSCs
generated by all three groups. This problem is not unique to the pig, as it has been reported in
other species as well [39]. In any case, the continued expression of pluripotency genes did not
pose any problems for the differentiation of the cells, since all three laboratories demonstrated
that their cell lines were able to differentiate in vitro (including EB formation) and in vivo by
forming teratomas containing cells of all three germ layers. More recently, it was demonstrated
that porcine iPSCs can form chimeras with high efficiency (85.3%), and contribute to all three
germ layers [44]. Because germline chimerism was not confirmed in this study, it remains to
be determined whether the porcine iPSCs are fully equivalent to mouse iPSCs.
One of the major advantages iPSCs may offer in the future is the potential for custom derivation
of pluripotent cells from individual patients to use for regenerative therapies without the risk
of immune rejection. However, since the epigenetic reprogramming necessary to produce
them requires prolonged expression of the transgenes (2-3 weeks), most of the iPSCs described
to date have been generated with the use of lentiviral vectors that integrate known oncogenes
(such as c-myc and Klf4) into the cell genome. The dangers of using these genes became evident
in a study in which mouse chimeras generated with iPSCs developed tumors following
reactivation of the initially silenced transgene c-myc [38]. In the only report to date in which
porcine chimeras were produced from iPSCs [44], no tumor formation was reported in the
newborn piglets. However, because long-term testing and monitoring were not conducted
prior to the publication of these results, at present there is no guarantee that these iPSCs would
be safe for clinical applications.
To avoid problems associated with viral integration and the use of oncogenes, many groups
have developed strategies for iPSC production in which the disadvantages discussed above
have been minimized. For example, it has been shown that reprogramming can be achieved
in both human and mouse cells without the use of c-myc, albeit at the expense of efficiency [45].
In addition, the use of certain transcription factors can be omitted when using cell types already
expressing them; for example, neural progenitor cells, which already express endogenous Sox2
and c-myc were reprogrammed using only the induced expression of OCT4 and Klf4 [46] [47].
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Furthermore, some transcription factors can be replaced by small molecules that have similar
effects on somatic cell reprogramming [48]. Viral integration, which carries risks of insertional
mutagenesis, can be avoided by using nonintegrating adenoviral vectors [49] [50]. Our
laboratory has established porcine iPSCs derived from pig skin fibroblasts using Sendai virus
vectors to introduce 4 human transcription factors (OCT4, SOX2, c-Myc, and KLF4) (data not
shown). Another attractive alternative to the use of viral vectors are transposon vectors, which
combine high transfection efficiency with enhanced safety, and can be removed from the cell
genomes following reprogramming. For example, piggyBac is a DNA transposon that,
following insertion, can be removed from the reprogrammed genome without leaving a trace.
This transposon has already been used successfully to produce iPSCs [51, 52]. Finally, Zhou
[53] produced iPSCs by providing the transcription factors in the form of recombinant proteins.
With regard to future research in porcine iPSC production, the choice of cell type and strategy
will undoubtedly play an important role in the reprogramming efficiency. It should be noted,
however, that the same problems existing in porcine ESC culture are likely to affect the long-
term maintenance of the newly generated pig iPSC lines. For example, the culture conditions
supporting the pluripotency and self-renewal of the porcine iPSCs apparently require further
optimization, given that, in all the published reports to date, the reprogrammed cell lines could
be maintained only with the continued expression of exogenous pluripotency genes. In one
study, for example, instead of using growth factors or other supplements, the pig iPSCs were
maintained with doxycycline-induced expression of the pluripotency transgenes, until the
authors chose to differentiate the cells [41].
Despite these challenges, we can without doubt look forward to an exciting future in which
iPSCs will add another dimension to pluripotent stem cell research in the pig.
5. Epiblast stem cells
Epiblast stem cells are pluripotent stem cells derived from the epiblast layer of post-implan‐
tation mouse embryos [54]. Epiblast stem cells are distinct from ES cells, which are derived
from the inner cell mass of blastocysts. Both ES cells and epiblast stem cells can differentiate
into mesoderm, endoderm, and ectoderm. However, epiblast stem cells do not have germ-line
transmission.
Rodent pluripotent stem cells are considered to have two distinct states: naïve and primed.
Naïve pluripotent stem cell lines are distinguished from primed cells in their response to LIF
signaling and MEK/GSK3 inhibition (LIF/2i conditions) and X chromosome activation. Human
ES and iPS cells both resemble rodent primed epiblast stem cells more closely than rodent
naïve ES cells. In addition, iPS cells derived from pigs can obtain the properties of primed
epiblast stem cells. iPS cells derived from human, monkey, rabbit, and rat, but not mouse, can
also obtain the properties of primed epiblast stem cells [55].
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6. Conclusions
Stem cell biology research of the minipig is developing rapidly. Although studies on mouse
and human stem cells currently outnumber those of other species, data from these well-studied
species provide a good foundation for current and future porcine stem cell research. Despite
the challenges associated with developing porcine pluripotent stem cells, recent successes in
the fields of induced pluripotent stem cells and somatic stem cells suggest that minipig stem
cell research has a promising future.
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